RaQualia Pharma (TSE:4579) Interest Expense: 円-31 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
59 GF Score
Price 円458.00
GF Value 円310.31
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma Interest Expense?

RaQualia Pharma TSE:4579 -3.78% 59 Interest Expense is 円-31 Mil as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 59/100 and a GF Value™ of 円310.31 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. RaQualia Pharma's interest expense for the three months ended in Mar. 2026 was 円 -15 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円-31 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. RaQualia Pharma's Operating Income for the three months ended in Mar. 2026 was 円 -160 Mil. RaQualia Pharma's Interest Expense for the three months ended in Mar. 2026 was 円 -15 Mil. RaQualia Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RaQualia Pharma  (TSE:4579) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RaQualia Pharma's Interest Expense for the three months ended in Mar. 2026 was 円-15 Mil. Its Operating Income for the three months ended in Mar. 2026 was 円-160 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was 円2,191 Mil.

RaQualia Pharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

RaQualia Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

RaQualia Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Interest Expense Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.45 -6.00 -6.68 -42.62 -59.06

RaQualia Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.47 -15.71 0.00 0.00 -15.16
TSE:4579
59GF Score
RaQualia Pharma Inc TSE:4579
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of 円-31 Mil mean?
RaQualia Pharma (TSE:4579) has a Interest Expense of 円-31 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Interest Expense too high?
RaQualia Pharma's current Interest Expense is 円-31 Mil. Overall, RaQualia Pharma has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Interest Expense compare to VRTX and REGN?
RaQualia Pharma's Interest Expense of 円-31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Interest Expense is 円-31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.31, compared to a current price of 円458.00 — trading 47.6% above its estimated fair value. The current Interest Expense is 円-31 Mil. RaQualia Pharma's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Interest Expense is 円-31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円458.00 is trading 47.6% above its estimated GF Value™ of 円310.31. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • Interest Expense: 円-31 Mil
  • GF Value™: 円310.31 vs. price of 円458.00 (47.6% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
59GF Score

Get the complete analysis for TSE:4579

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円458.00
Price
円310.31
GF Value